Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Allergic asthma and omalizumab--the experience at the Centro Hospitalar da Cova da Beira.

Simões Saldanha Mendes M, Valente MJ, Vicente I, Magalhães E, Valente S.

Rev Port Pneumol. 2013 Jul-Aug;19(4):186-7. doi: 10.1016/j.rppneu.2013.03.003. Epub 2013 Jun 2. English, Portuguese. No abstract available.

2.

Omalizumab for severe allergic asthma: 7 years and open questions.

Solèr M.

Respiration. 2014;88(2):158-61. doi: 10.1159/000360771. Epub 2014 May 9. Review.

PMID:
24818580
3.

Should clinicians use omalizumab for the treatment of nasal polyps?

Naclerio RM, Baroody FM, Pinto JM.

J Allergy Clin Immunol. 2013 Jul;132(1):247. doi: 10.1016/j.jaci.2013.04.001. Epub 2013 May 16. No abstract available.

PMID:
23684073
4.

Echinococcus multilocularis infection in a patient treated with omalizumab.

Skiepko R, Zietkowski Z, Skiepko U, Tomasiak-Lozowska MM, Bodzenta-Lukaszyk A.

J Investig Allergol Clin Immunol. 2013;23(3):199-200. No abstract available.

5.

Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis.

Matito A, Blázquez-Goñi C, Morgado JM, Alvarez-Twose I, Mollejo M, Sánchez-Muñoz L, Escribano L.

Ann Allergy Asthma Immunol. 2013 Nov;111(5):425-6. doi: 10.1016/j.anai.2013.08.014. Epub 2013 Sep 21. No abstract available.

PMID:
24125156
6.

Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma.

Tajiri T, Matsumoto H, Hiraumi H, Ikeda H, Morita K, Izuhara K, Ono J, Ohta S, Ito I, Oguma T, Nakaji H, Inoue H, Iwata T, Nagasaki T, Kanemitsu Y, Ito J, Niimi A, Mishima M.

Ann Allergy Asthma Immunol. 2013 May;110(5):387-8. doi: 10.1016/j.anai.2013.01.024. Epub 2013 Feb 23. No abstract available.

PMID:
23622013
7.

[Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications].

Kupryś-Lipińska I, Kuna P.

Pneumonol Alergol Pol. 2009;77(1):43-51. Review. Polish.

8.

Anti-IgE--emerging opportunities for Omalizumab.

Babu KS, Polosa R, Morjaria JB.

Expert Opin Biol Ther. 2013 May;13(5):765-77. doi: 10.1517/14712598.2013.782391. Epub 2013 Mar 22. Review.

PMID:
23517576
9.

Differences in effects of omalizumab on late-phase responses to allergen challenge in the skin and nose at the time of basophil hyporesponsiveness.

Paterniti MO, Breslin LM, Courneya JP, Sterba PM, Hamilton RG, MacGlashan DW Jr, Saini SS.

J Invest Dermatol. 2014 Jun;134(6):1743-4. doi: 10.1038/jid.2013.541. Epub 2013 Dec 23. No abstract available.

10.

Reply: To PMID 23021878.

Calus L, Hellings P, Brusselle G, Bachert C, Gevaert P.

J Allergy Clin Immunol. 2013 Jul;132(1):247-8. doi: 10.1016/j.jaci.2013.04.002. Epub 2013 May 16. No abstract available.

PMID:
23684071
11.

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.

Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, Hellings P, Brusselle G, De Bacquer D, van Cauwenberge P, Bachert C.

J Allergy Clin Immunol. 2013 Jan;131(1):110-6.e1. doi: 10.1016/j.jaci.2012.07.047. Epub 2012 Sep 27.

PMID:
23021878
12.

Basophil activation test: do not lose control.

Maietta G.

Eur Ann Allergy Clin Immunol. 2015 Mar;47(2):36-7. No abstract available.

PMID:
25781191
13.

Biologics and the treatment of chronic rhinosinusitis.

Kern RC.

J Allergy Clin Immunol. 2013 Jan;131(1):117-8. doi: 10.1016/j.jaci.2012.11.021. No abstract available.

PMID:
23265697
14.

Anti-IgE therapy: clinical utility beyond asthma.

Casale TB, Stokes J.

J Allergy Clin Immunol. 2009 Apr;123(4):770-1.e1. doi: 10.1016/j.jaci.2009.02.016. No abstract available.

PMID:
19348915
15.

Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma.

Somerville L, Bardelas J, Viegas A, D'Andrea P, Blogg M, Peachey G.

Curr Med Res Opin. 2014 Jan;30(1):59-66. doi: 10.1185/03007995.2013.844115. Epub 2013 Oct 1.

PMID:
24028677
16.

Difficult asthma and Churg-Strauss-like syndrome: a cautionary tale.

Lau EM, Cooper W, Bye PT, Yan K.

Respirology. 2011 Jan;16(1):180-1. doi: 10.1111/j.1440-1843.2010.01884.x. No abstract available.

PMID:
21504509
17.

A case of allergic bronchopulmonary aspergillosis treated with omalizumab.

Sastre I, Blanco J, Mata H, García F.

J Investig Allergol Clin Immunol. 2012;22(2):145-7. No abstract available.

18.

Aspirin tolerance following omalizumab therapy in a patient with aspirin-exacerbated respiratory disease.

Aksu K, Kurt E.

Allergol Immunopathol (Madr). 2013 May-Jun;41(3):208-10. doi: 10.1016/j.aller.2012.02.005. Epub 2012 Jul 2. No abstract available.

PMID:
22763305
19.

Omalizumab for chronic urticaria.

Altman MC, Naimi DR.

N Engl J Med. 2013 Jun 27;368(26):2528-30. doi: 10.1056/NEJMc1305687#SA3. No abstract available.

PMID:
23802532
20.

Omalizumab for chronic urticaria.

Benelli E, Ventura A.

N Engl J Med. 2013 Jun 27;368(26):2528. doi: 10.1056/NEJMc1305687#SA2. No abstract available.

PMID:
23802531

Supplemental Content

Support Center